About · Founder
Christelle Sanglier-Bornstein
Founder & CEO, Concordat Bio. Former principal-level BD at Novartis.
Christelle Sanglier-Bornstein has led and supported 20+ strategic transactions totaling more than USD 100 billion in aggregate deal value at Novartis — acquisitions, licensing agreements, divestitures, carve-outs, and one of the industry’s largest pharmaceutical spin-offs. She’s negotiated with C-suite counterparties, run due diligence under deal-clock pressure, and owned integration through to value realization, not just signature.
She built Concordat Bio because she watched lean BD teams lose winnable deals to timeline and bandwidth, not judgment — the same gap McKinsey and Deloitte charge $500K–$2M to patch project-by-project. Concordat runs that capability every night, permanently, for a fraction of the cost.
Track record
What she has owned end-to-end.
Five deal shapes a lean BD desk rarely finishes the same way twice. Concordat Bio is the platformization of those plays — the playbook, applied every day, without the personnel turnaround that erodes institutional knowledge between transactions.
Acquisitions
Tuck-in and platform deals, with integration playbooks drawn from the actual work — not from templates a consulting firm borrowed from its last engagement.
Licensing agreements
In-licensing and out-licensing across modalities and stages, negotiated against the portfolio gaps the buyer has named in advance.
Divestitures
Non-core asset sales to strategic and financial buyers, with the structuring work executed before — rather than after — counterparty selection.
Carve-outs
Separation of business units, with the operational disentanglement that BD leaders rarely see end-to-end.
Spin-off
One of the industry’s largest pharmaceutical spin-offs — separation science, not a press release.
Get started
Put Concordat Bio through a pilot on a single high-priority candidate.
Pilots run on a single high-priority candidate for one customer-defined portfolio gap — one workspace, one NDA, one set of deliverables. If the BD outputs hold up, you decide whether to expand.
Concordat Bio · Basel, CH · Tenant-isolated SaaS.
Direct line
concordat-bio@polsia.app